Post-traumatic Stress Disorder (PTSD) - Pipeline Insight, 2024

Post-traumatic Stress Disorder (PTSD) - Pipeline Insight, 2024

DelveInsight’s, “Post-traumatic Stress Disorder (PTSD) - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Post-traumatic Stress Disorder (PTSD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Post-traumatic Stress Disorder (PTSD): Understanding

Post-traumatic Stress Disorder (PTSD): Overview

Post-traumatic stress disorder (PTSD) is a disabling psychiatric disorder that results from being exposed to real or threatened injury, death, and sexual assault. It is associated with functional and cognitive impairment. Early diagnosis and intervention are necessary for effective treatment and to minimize the long-term outcomes associated with PTSD. PTSD is a disorder that develops in some people who have experienced a shocking, scary, or dangerous event. It is natural to feel afraid during and after a traumatic situation. Fear is a part of the body’s “fight-or-flight” response, which helps us avoid or respond to potential danger. People may experience a range of reactions after trauma, and most people recover from initial symptoms over time. Those who continue to experience problems may be diagnosed with PTSD. Anyone can develop PTSD at any age. This includes combat veterans and people who have experienced or witnessed a physical or sexual assault, abuse, an accident, a disaster, or other serious events. People who have PTSD may feel stressed or frightened, even when they are not in danger.

The pathophysiology of Post-traumatic stress disorder involves alterations in the neurotransmitter and neurohormonal functioning. Individuals with PTSD have shown to have normal to low levels of cortisol and elevated levels of corticotropin-releasing factor (CRF) despite their ongoing stress. CRF stimulates the release of norepinephrine by the anterior cingulate cortex, which leads to an increased sympathetic response, which manifests as increased heart rate, blood pressure, increased arousal, and startle response. PTSD is associated with the change in the neurophysiology and anatomy of the brain. The size of the hippocampus is reduced, and the amygdala (processing emotions and modulating fear response) is overly reactive in individuals with PTSD. The medial prefrontal cortex (inhibitory control over the emotional reactivity of amygdala) appears to be smaller and less responsive in patients with PTSD.

Post-traumatic stress disorder is a complex phenomenon, and it is necessary to evaluate for any co-existing psychiatric illness in the patient. After a detailed history is obtained, the next step is to have a thorough mental status examination, which helps confirm the behavioral, emotional, and cognitive aspects of PTSD. On the mental status examination, the patient would likely mention poor sleep and concentration, frequent nightmares and flashbacks related to the event, guilt or negative emotions associated with the reminder, avoidance, and increased vigilance. Post-traumatic stress disorder is a disabling consequence after a traumatic event, and early detection and intervention are necessary for planning the management. Studies have shown that both psychotherapy and pharmacotherapy are effective. Trauma-focused psychotherapy is considered as the first-line treatment effective in adults as well as children, and it includes trauma-focused CBT (cognitive-behavioral therapy), eye movement desensitization and reprocessing (EMDR), cognitive processing therapy, and imaginal exposure. Studies have shown that daytime PTSD symptoms improve even after a single session of CBT. The therapy has shown to shorten the course of those who will recover. However, it does not change the long-term outcome. Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) are the first-line drug of choice for the treatment of PTSD. Sertraline and paroxetine are Food and Drug Administration (FDA)-approved medications for adults.

""Post-traumatic Stress Disorder (PTSD) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Post-traumatic Stress Disorder (PTSD) pipeline landscape is provided which includes the disease overview and Post-traumatic Stress Disorder (PTSD) treatment guidelines. The assessment part of the report embraces, in depth Post-traumatic Stress Disorder (PTSD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Post-traumatic Stress Disorder (PTSD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Post-traumatic Stress Disorder (PTSD) R&D. The therapies under development are focused on novel approaches to treat/improve Post-traumatic Stress Disorder (PTSD).

Post-traumatic Stress Disorder (PTSD) Emerging Drugs Chapters

This segment of the Post-traumatic Stress Disorder (PTSD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Post-traumatic Stress Disorder (PTSD) Emerging Drugs

• Brexpiprazole: Otsuka Pharmaceutical Development & Commercialization

Brexpiprazole is a Dopamine D2 receptor partial agonists being developed by Otsuka Pharmaceutical Development and Commercialization in a Phase III clinical trial for Post-Traumatic stress disorder. Brexpiprazole as Combination Therapy with Sertraline is tested in the Adults with Post-traumatic Stress Disorder.

• BNC210: Bionomics Limited

BNC210 (also known as IW-2143 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor by Bionomics Limited. It is currently being investigated for the treatment of post-traumatic stress disorder. The drug has demonstrated clinically significant anxiety reduction in both animal models and in Phase I trials. It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models. It is a negative-allosteric modulator of the alpha-7 nicotinic receptor. It binds at a site distant from the traditional nicotine binding site for which this receptor is named, (binding acetylcholine in-vivo), and decreases the activity of the ligand gated ion channel. This has downstream effects, similar to, inhibition at this site. Acetylcholine, while being used very widely and commonly in mammals, is especially prominent in the function of memory and Long-Term Potentiation. It is currently in Phase II stage of development.

• Lu AG06466: H. Lundbeck A/S

Lu AG06466 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). H.Lundbeck A/S is conducting Phase I trial for Lu AG06466 after multiple doses of 30 milligrams (mg) in participants with PTSD.

Further product details are provided in the report……..

Post-traumatic Stress Disorder (PTSD): Therapeutic Assessment

This segment of the report provides insights about the different Post-traumatic Stress Disorder (PTSD) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Post-traumatic Stress Disorder (PTSD)
• There are approx. 20+ key companies which are developing the therapies for Post-traumatic Stress Disorder (PTSD). The companies which have their Post-traumatic Stress

Disorder (PTSD) drug candidates in the most advanced stage, i.e. Phase III include, Otsuka Pharmaceutical

• Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Post-traumatic Stress Disorder (PTSD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Post-traumatic Stress Disorder (PTSD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Post-traumatic Stress Disorder (PTSD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Post-traumatic Stress Disorder (PTSD) drugs.

Post-traumatic Stress Disorder (PTSD) Report Insights

• Post-traumatic Stress Disorder (PTSD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Post-traumatic Stress Disorder (PTSD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Post-traumatic Stress Disorder (PTSD) drugs?
• How many Post-traumatic Stress Disorder (PTSD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Post-traumatic Stress Disorder (PTSD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Post-traumatic Stress Disorder (PTSD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Post-traumatic Stress Disorder (PTSD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tonix Pharmaceuticals, Inc.
• Pop Test Oncology LLC
• H. Lundbeck A/S
• Bionomics Limited
• Alto Neuroscience

Key Products

• TNX-102
• PT150
• Lu AG06466
• BNC210
• ALTO-100